Characterizing and Minimizing Aggregation and Particle Formation of Three Recombinant Fusion-Protein Bulk Antigens for Use in a Candidate Trivalent Rotavirus Vaccine

In a companion paper, the structural integrity, conformational stability, and degradation mechanisms of 3 recombinant fusion-protein antigens comprising a non-replicating rotavirus (NRRV) vaccine candidate (currently being evaluated in early-stage clinical trials) are described. In this work, we foc...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of pharmaceutical sciences 2020-01, Vol.109 (1), p.394-406
Hauptverfasser: Agarwal, Sanjeev, Sahni, Neha, Hickey, John M., Robertson, George A., Sitrin, Robert, Cryz, Stanley, Joshi, Sangeeta B., Volkin, David B.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 406
container_issue 1
container_start_page 394
container_title Journal of pharmaceutical sciences
container_volume 109
creator Agarwal, Sanjeev
Sahni, Neha
Hickey, John M.
Robertson, George A.
Sitrin, Robert
Cryz, Stanley
Joshi, Sangeeta B.
Volkin, David B.
description In a companion paper, the structural integrity, conformational stability, and degradation mechanisms of 3 recombinant fusion-protein antigens comprising a non-replicating rotavirus (NRRV) vaccine candidate (currently being evaluated in early-stage clinical trials) are described. In this work, we focus on the aggregation propensity of the 3 NRRV antigens coupled to formulation development studies to identify common frozen bulk candidate formulations. The P2-VP8-P[8] antigen was most susceptible to shaking and freeze-thaw–induced aggregation and particle formation. Each NRRV antigen formed aggregates with structurally altered protein (with exposed apolar regions and intermolecular β-sheet) and dimers containing a non-native disulfide bond. From excipient screening studies with P2-VP8-P[8], sugars or polyols (e.g., sucrose, trehalose, mannitol, sorbitol) and various detergents (e.g., Pluronic F-68, polysorbate 20 and 80, PEG-3350) were identified as stabilizers against aggregation. By combining promising additives, candidate bulk formulations were optimized to not only minimize agitation-induced aggregation, but also particle formation due to freeze-thaw stress of P2-VP8-P[8] antigen. Owing to limited material availability, stabilization of the P2-VP8-P[4] and P2-VP8-P[6] was confirmed with the lead candidate P2-VP8-P[8] formulations. The optimization of these bulk NRRV candidate formulations is discussed in the context of subsequent drug product formulations in the presence of aluminum adjuvants.
doi_str_mv 10.1016/j.xphs.2019.08.001
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6941221</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022354919304940</els_id><sourcerecordid>2271841270</sourcerecordid><originalsourceid>FETCH-LOGICAL-c455t-913cf11b0c7dec8781582f64f62067ff2fbfd1b51cd16cec30b0808bd96aa83b3</originalsourceid><addsrcrecordid>eNp9kc1u1DAUhSMEotPCC7BAXrJJuHZ-R0JIw4gBpCKqasrWcpzrjIfEntrOCPo-vCceUirYsLLsc853r3yS5AWFjAKtXu-z74edzxjQZQZNBkAfJQtaMkgroPXjZAHAWJqXxfIsOfd-DwAVlOXT5CynBUBeVIvk53onnJABnb7TpifCdOSzNnqcr6u-d9iLoK35LV0JF7QckGysG-dnq8h25xDJNUo7ttoIE8hm8lFLr5wNqA15Nw3fyMoE3aPxRFlHbjySKAiyjljdiYBk6_RRDBjT1zaIo3aTJ1-FlNrgs-SJEoPH5_fnRXKzeb9df0wvv3z4tF5dprIoy5AuaS4VpS3IukPZ1A0tG6aqQlUMqlopplrV0baksqOVRJlDCw00bbeshGjyNr9I3s7cw9SO2Mm4jBMDPzg9CveDW6H5v4rRO97bI6-WBWWMRsCre4CztxP6wEftJQ6DMGgnzxmraROtNUQrm63SWe8dqocxFPipX77np375qV8ODY_9xtDLvxd8iPwpNBrezAaM33TU6LiXGo3ETjuUgXdW_4__Cz_Lu-M</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2271841270</pqid></control><display><type>article</type><title>Characterizing and Minimizing Aggregation and Particle Formation of Three Recombinant Fusion-Protein Bulk Antigens for Use in a Candidate Trivalent Rotavirus Vaccine</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Agarwal, Sanjeev ; Sahni, Neha ; Hickey, John M. ; Robertson, George A. ; Sitrin, Robert ; Cryz, Stanley ; Joshi, Sangeeta B. ; Volkin, David B.</creator><creatorcontrib>Agarwal, Sanjeev ; Sahni, Neha ; Hickey, John M. ; Robertson, George A. ; Sitrin, Robert ; Cryz, Stanley ; Joshi, Sangeeta B. ; Volkin, David B.</creatorcontrib><description>In a companion paper, the structural integrity, conformational stability, and degradation mechanisms of 3 recombinant fusion-protein antigens comprising a non-replicating rotavirus (NRRV) vaccine candidate (currently being evaluated in early-stage clinical trials) are described. In this work, we focus on the aggregation propensity of the 3 NRRV antigens coupled to formulation development studies to identify common frozen bulk candidate formulations. The P2-VP8-P[8] antigen was most susceptible to shaking and freeze-thaw–induced aggregation and particle formation. Each NRRV antigen formed aggregates with structurally altered protein (with exposed apolar regions and intermolecular β-sheet) and dimers containing a non-native disulfide bond. From excipient screening studies with P2-VP8-P[8], sugars or polyols (e.g., sucrose, trehalose, mannitol, sorbitol) and various detergents (e.g., Pluronic F-68, polysorbate 20 and 80, PEG-3350) were identified as stabilizers against aggregation. By combining promising additives, candidate bulk formulations were optimized to not only minimize agitation-induced aggregation, but also particle formation due to freeze-thaw stress of P2-VP8-P[8] antigen. Owing to limited material availability, stabilization of the P2-VP8-P[4] and P2-VP8-P[6] was confirmed with the lead candidate P2-VP8-P[8] formulations. The optimization of these bulk NRRV candidate formulations is discussed in the context of subsequent drug product formulations in the presence of aluminum adjuvants.</description><identifier>ISSN: 0022-3549</identifier><identifier>EISSN: 1520-6017</identifier><identifier>DOI: 10.1016/j.xphs.2019.08.001</identifier><identifier>PMID: 31400346</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>aggregation ; Antigens, Viral - chemistry ; Drug Compounding ; Drug Stability ; Drug Storage ; Drugs, Investigational - chemistry ; Excipients - chemistry ; formulation ; Freezing ; Particle Size ; Pharmaceutical Biotechnology ; Protein Aggregates ; Protein Stability ; Recombinant Fusion Proteins - chemistry ; recombinant protein ; rotavirus ; Rotavirus Vaccines - chemistry ; stability ; subunit vaccine ; Vaccines, Subunit - chemistry</subject><ispartof>Journal of pharmaceutical sciences, 2020-01, Vol.109 (1), p.394-406</ispartof><rights>2020 The Authors</rights><rights>Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.</rights><rights>2019 The Authors. 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c455t-913cf11b0c7dec8781582f64f62067ff2fbfd1b51cd16cec30b0808bd96aa83b3</citedby><cites>FETCH-LOGICAL-c455t-913cf11b0c7dec8781582f64f62067ff2fbfd1b51cd16cec30b0808bd96aa83b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,778,782,883,27907,27908</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31400346$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Agarwal, Sanjeev</creatorcontrib><creatorcontrib>Sahni, Neha</creatorcontrib><creatorcontrib>Hickey, John M.</creatorcontrib><creatorcontrib>Robertson, George A.</creatorcontrib><creatorcontrib>Sitrin, Robert</creatorcontrib><creatorcontrib>Cryz, Stanley</creatorcontrib><creatorcontrib>Joshi, Sangeeta B.</creatorcontrib><creatorcontrib>Volkin, David B.</creatorcontrib><title>Characterizing and Minimizing Aggregation and Particle Formation of Three Recombinant Fusion-Protein Bulk Antigens for Use in a Candidate Trivalent Rotavirus Vaccine</title><title>Journal of pharmaceutical sciences</title><addtitle>J Pharm Sci</addtitle><description>In a companion paper, the structural integrity, conformational stability, and degradation mechanisms of 3 recombinant fusion-protein antigens comprising a non-replicating rotavirus (NRRV) vaccine candidate (currently being evaluated in early-stage clinical trials) are described. In this work, we focus on the aggregation propensity of the 3 NRRV antigens coupled to formulation development studies to identify common frozen bulk candidate formulations. The P2-VP8-P[8] antigen was most susceptible to shaking and freeze-thaw–induced aggregation and particle formation. Each NRRV antigen formed aggregates with structurally altered protein (with exposed apolar regions and intermolecular β-sheet) and dimers containing a non-native disulfide bond. From excipient screening studies with P2-VP8-P[8], sugars or polyols (e.g., sucrose, trehalose, mannitol, sorbitol) and various detergents (e.g., Pluronic F-68, polysorbate 20 and 80, PEG-3350) were identified as stabilizers against aggregation. By combining promising additives, candidate bulk formulations were optimized to not only minimize agitation-induced aggregation, but also particle formation due to freeze-thaw stress of P2-VP8-P[8] antigen. Owing to limited material availability, stabilization of the P2-VP8-P[4] and P2-VP8-P[6] was confirmed with the lead candidate P2-VP8-P[8] formulations. The optimization of these bulk NRRV candidate formulations is discussed in the context of subsequent drug product formulations in the presence of aluminum adjuvants.</description><subject>aggregation</subject><subject>Antigens, Viral - chemistry</subject><subject>Drug Compounding</subject><subject>Drug Stability</subject><subject>Drug Storage</subject><subject>Drugs, Investigational - chemistry</subject><subject>Excipients - chemistry</subject><subject>formulation</subject><subject>Freezing</subject><subject>Particle Size</subject><subject>Pharmaceutical Biotechnology</subject><subject>Protein Aggregates</subject><subject>Protein Stability</subject><subject>Recombinant Fusion Proteins - chemistry</subject><subject>recombinant protein</subject><subject>rotavirus</subject><subject>Rotavirus Vaccines - chemistry</subject><subject>stability</subject><subject>subunit vaccine</subject><subject>Vaccines, Subunit - chemistry</subject><issn>0022-3549</issn><issn>1520-6017</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc1u1DAUhSMEotPCC7BAXrJJuHZ-R0JIw4gBpCKqasrWcpzrjIfEntrOCPo-vCceUirYsLLsc853r3yS5AWFjAKtXu-z74edzxjQZQZNBkAfJQtaMkgroPXjZAHAWJqXxfIsOfd-DwAVlOXT5CynBUBeVIvk53onnJABnb7TpifCdOSzNnqcr6u-d9iLoK35LV0JF7QckGysG-dnq8h25xDJNUo7ttoIE8hm8lFLr5wNqA15Nw3fyMoE3aPxRFlHbjySKAiyjljdiYBk6_RRDBjT1zaIo3aTJ1-FlNrgs-SJEoPH5_fnRXKzeb9df0wvv3z4tF5dprIoy5AuaS4VpS3IukPZ1A0tG6aqQlUMqlopplrV0baksqOVRJlDCw00bbeshGjyNr9I3s7cw9SO2Mm4jBMDPzg9CveDW6H5v4rRO97bI6-WBWWMRsCre4CztxP6wEftJQ6DMGgnzxmraROtNUQrm63SWe8dqocxFPipX77np375qV8ODY_9xtDLvxd8iPwpNBrezAaM33TU6LiXGo3ETjuUgXdW_4__Cz_Lu-M</recordid><startdate>20200101</startdate><enddate>20200101</enddate><creator>Agarwal, Sanjeev</creator><creator>Sahni, Neha</creator><creator>Hickey, John M.</creator><creator>Robertson, George A.</creator><creator>Sitrin, Robert</creator><creator>Cryz, Stanley</creator><creator>Joshi, Sangeeta B.</creator><creator>Volkin, David B.</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20200101</creationdate><title>Characterizing and Minimizing Aggregation and Particle Formation of Three Recombinant Fusion-Protein Bulk Antigens for Use in a Candidate Trivalent Rotavirus Vaccine</title><author>Agarwal, Sanjeev ; Sahni, Neha ; Hickey, John M. ; Robertson, George A. ; Sitrin, Robert ; Cryz, Stanley ; Joshi, Sangeeta B. ; Volkin, David B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c455t-913cf11b0c7dec8781582f64f62067ff2fbfd1b51cd16cec30b0808bd96aa83b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>aggregation</topic><topic>Antigens, Viral - chemistry</topic><topic>Drug Compounding</topic><topic>Drug Stability</topic><topic>Drug Storage</topic><topic>Drugs, Investigational - chemistry</topic><topic>Excipients - chemistry</topic><topic>formulation</topic><topic>Freezing</topic><topic>Particle Size</topic><topic>Pharmaceutical Biotechnology</topic><topic>Protein Aggregates</topic><topic>Protein Stability</topic><topic>Recombinant Fusion Proteins - chemistry</topic><topic>recombinant protein</topic><topic>rotavirus</topic><topic>Rotavirus Vaccines - chemistry</topic><topic>stability</topic><topic>subunit vaccine</topic><topic>Vaccines, Subunit - chemistry</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Agarwal, Sanjeev</creatorcontrib><creatorcontrib>Sahni, Neha</creatorcontrib><creatorcontrib>Hickey, John M.</creatorcontrib><creatorcontrib>Robertson, George A.</creatorcontrib><creatorcontrib>Sitrin, Robert</creatorcontrib><creatorcontrib>Cryz, Stanley</creatorcontrib><creatorcontrib>Joshi, Sangeeta B.</creatorcontrib><creatorcontrib>Volkin, David B.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of pharmaceutical sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Agarwal, Sanjeev</au><au>Sahni, Neha</au><au>Hickey, John M.</au><au>Robertson, George A.</au><au>Sitrin, Robert</au><au>Cryz, Stanley</au><au>Joshi, Sangeeta B.</au><au>Volkin, David B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Characterizing and Minimizing Aggregation and Particle Formation of Three Recombinant Fusion-Protein Bulk Antigens for Use in a Candidate Trivalent Rotavirus Vaccine</atitle><jtitle>Journal of pharmaceutical sciences</jtitle><addtitle>J Pharm Sci</addtitle><date>2020-01-01</date><risdate>2020</risdate><volume>109</volume><issue>1</issue><spage>394</spage><epage>406</epage><pages>394-406</pages><issn>0022-3549</issn><eissn>1520-6017</eissn><abstract>In a companion paper, the structural integrity, conformational stability, and degradation mechanisms of 3 recombinant fusion-protein antigens comprising a non-replicating rotavirus (NRRV) vaccine candidate (currently being evaluated in early-stage clinical trials) are described. In this work, we focus on the aggregation propensity of the 3 NRRV antigens coupled to formulation development studies to identify common frozen bulk candidate formulations. The P2-VP8-P[8] antigen was most susceptible to shaking and freeze-thaw–induced aggregation and particle formation. Each NRRV antigen formed aggregates with structurally altered protein (with exposed apolar regions and intermolecular β-sheet) and dimers containing a non-native disulfide bond. From excipient screening studies with P2-VP8-P[8], sugars or polyols (e.g., sucrose, trehalose, mannitol, sorbitol) and various detergents (e.g., Pluronic F-68, polysorbate 20 and 80, PEG-3350) were identified as stabilizers against aggregation. By combining promising additives, candidate bulk formulations were optimized to not only minimize agitation-induced aggregation, but also particle formation due to freeze-thaw stress of P2-VP8-P[8] antigen. Owing to limited material availability, stabilization of the P2-VP8-P[4] and P2-VP8-P[6] was confirmed with the lead candidate P2-VP8-P[8] formulations. The optimization of these bulk NRRV candidate formulations is discussed in the context of subsequent drug product formulations in the presence of aluminum adjuvants.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>31400346</pmid><doi>10.1016/j.xphs.2019.08.001</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0022-3549
ispartof Journal of pharmaceutical sciences, 2020-01, Vol.109 (1), p.394-406
issn 0022-3549
1520-6017
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6941221
source MEDLINE; Alma/SFX Local Collection
subjects aggregation
Antigens, Viral - chemistry
Drug Compounding
Drug Stability
Drug Storage
Drugs, Investigational - chemistry
Excipients - chemistry
formulation
Freezing
Particle Size
Pharmaceutical Biotechnology
Protein Aggregates
Protein Stability
Recombinant Fusion Proteins - chemistry
recombinant protein
rotavirus
Rotavirus Vaccines - chemistry
stability
subunit vaccine
Vaccines, Subunit - chemistry
title Characterizing and Minimizing Aggregation and Particle Formation of Three Recombinant Fusion-Protein Bulk Antigens for Use in a Candidate Trivalent Rotavirus Vaccine
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T04%3A01%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Characterizing%20and%20Minimizing%20Aggregation%20and%20Particle%20Formation%20of%20Three%20Recombinant%20Fusion-Protein%20Bulk%20Antigens%20for%20Use%20in%20a%20Candidate%20Trivalent%20Rotavirus%20Vaccine&rft.jtitle=Journal%20of%20pharmaceutical%20sciences&rft.au=Agarwal,%20Sanjeev&rft.date=2020-01-01&rft.volume=109&rft.issue=1&rft.spage=394&rft.epage=406&rft.pages=394-406&rft.issn=0022-3549&rft.eissn=1520-6017&rft_id=info:doi/10.1016/j.xphs.2019.08.001&rft_dat=%3Cproquest_pubme%3E2271841270%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2271841270&rft_id=info:pmid/31400346&rft_els_id=S0022354919304940&rfr_iscdi=true